SecBot SecBot
Institutional Cluster

IRWD

IRONWOOD PHARMACEUTICALS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 4h ago
Institutional cluster: 8 buyers, 2 sellers (bullish)
Actionable Insight • Neutral

The cluster shows divergent institutional views: small asset managers are accumulating while two large holders (Citigroup, Deutsche Bank) are significantly reducing. The net selling suggests caution despite strong earnings. Monitor next quarter's 13F to see if the buying trend continues or reverses.

DirectionNeutral
Confidencemedium
Horizonweeks

Drug in focus

Linzess

● Neutral Named in this fund cluster
Impact
Phase
Approved / marketed (Phase 3 completed for the pediatric ages 2–5 sNDA)
Time to market
Already marketed in the U.S. since FDA approval in 2012; the only pending item was the pediatric (ages 2–5) label-expansion sNDA decided around its May 24, 2026 PDUFA date.
Next catalyst
None dated

What to watchFor ABBV holders, Linzess is immaterial to the thesis, treat it as steady, profitable co-marketed revenue, not a catalyst. Watch the 2026-08-06 IRWD Q2 earnings print (the co-commercialization partner) for Linzess U.S. net-sales momentum and any update on the ages 2–5 pediatric label decision from the May 2026 PDUFA, which the local data does not yet record as approved or rejected.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$4.81
T+0 close · Nov 9, 2026 · via day close
Latest settled
+1.25%
T+1 · $4.87
Vs SPY
−0.07%
α at T+1
Next horizon
T+5
in 5h
  1. T+0 · Nov 10 $4.81entry
  2. T+1 · 6d ago +1.25%α −0.07% · $4.87
  3. T+4 · todayOpen
  4. T+5 · in 5h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Eight institutional buyers accumulated $3.0M in new IRWD positions during Q3 2026, while two sellers reduced holdings by $4.9M, resulting in net selling of $1.9M. The buying cluster is dominated by asset managers who doubled or added positions, but the aggregate net dollar flow is negative due to large trims by Citigroup and Deutsche Bank. The cluster follows a strong Q3 earnings beat and raised guidance reported 5 days prior.

Key Financial Metrics

Direction
mixed
Buy Value
$3.7M
Sell Value
$4.9M
Net Flow
-$1.9M

Institutional Positions

Net institutional flow: -$1.9M

▲ Buyers (8)

InstitutionActionChangePosition ValueValue Δ
Principal Financial GroupDOUBLED+2551.8%$1.3M$1.2M
Lpl FinancialDOUBLED+1085.1%$1.2M$1.1M
Squarepoint OpsDOUBLED+184.9%$757.0K$475.0K

▼ Sellers (2)

InstitutionActionChangePrev ValueValue Δ
Deutsche BankNEAR_EXIT-86.1%$4.9M-$4.2M
CitigroupTRIM-65.9%$955.0K-$648.0K

Key Facts

  • 8 institutional buyers added $3.0M in new positions during Q3 2026
  • 2 institutional sellers reduced holdings by $4.9M, led by Deutsche Bank trimming $4.2M
  • Net institutional flow was negative $1.9M despite more buyers than sellers
  • Q3 2026 earnings beat consensus: revenue $133.0M vs $121.6M estimate, EPS $0.36 vs $0.31
  • Full-year 2026 guidance raised: LINZESS net sales to $1.20-$1.25B, total revenue to $485-$510M

Financial Impact

8 buyers added $3.0M in new positions while 2 sellers reduced by $4.9M, net outflow of $1.9M

institutional ownershipnet dollar flow

Risk Factors

  • 13F data is 45+ days stale; positions may have been unwound since quarter-end
  • Net selling by two large holders outweighs the buying cluster in dollar terms
  • No insider buying corroboration (confluence score 32/100, institutions only)
  • Deutsche Bank's near-exit (-86.1%) is a strong bearish signal from a major holder

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-IRWD-2026-Q3

Track record

13 reports on IRWD

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.35% at T+5 after the Nov 5, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.88 settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $4.84 settles Dec 15
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.81 settles Dec 9
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Viewing Entry $4.81 settles Dec 9
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $4.03 settles Dec 4
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $3.61 settles Nov 25
  7. Oct 16, 20264w ago 8-K Neutral 3/10 Entry $3.50 to $4.85 ▲ +38.57% +39.73% vs SPY
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $4.26 to $4.29 ▲ +0.70% +0.10% vs SPY
  9. May 13, 202626w ago 8-K Mixed 6/10 Entry $3.68 to $3.63 ▼ −1.36% −0.75% vs SPY
  10. May 7, 202627w ago 8-K Bullish 7/10 Entry $4.17 to $3.24 ▼ −22.30% −25.44% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 7h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026